-inferiority phase 3 trial . Lancet 2010 ; 376 : 91 – 102 . 32 Hughes KS Schnaper LA Berry D . Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer . N Engl J Med 2004 ; 351 : 971 – 977
Search Results
Advances in Breast Surgery, 2002-2012
Stephen B. Edge
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021
Featured Updates to the NCCN Guidelines
William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar
-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer . JAMA 2006 ; 295 : 1658 – 1667 . 16609087 10.1001/jama.295.14.1658 4. Paik S , Shak S , Tang G , A multigene assay to predict recurrence of tamoxifen
Mammographic Breast Density: Effect on Imaging and Breast Cancer Risk
Renee W. Pinsky and Mark A. Helvie
density changes risk. Tamoxifen has been proven to decrease breast cancer risk and cause decreased breast density in many women. 35 Making the mammogram less dense may also diminish the effect of masking. The antiestrogen effect of tamoxifen in the breast
Toward Less-Invasive Management of Early-Stage Breast Cancer
Amy Cyr
-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study . J Clin Oncol 2010 ; 28 : 1829 – 1834 . 5. Grotenhuis BA Vrijland WW Klem TM . Radiofrequency ablation for early
NCCN Guidelines Update: Evolving Radiation Therapy Recommendations for Breast Cancer
Kilian E. Salerno
. Hughes KS Schnaper LA Bellon JR . Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343 . J Clin Oncol 2013 ; 31 : 2382 – 2387 . 6. Kunkler IH
Long-Term Therapy of Venous Thromboembolism in Cancer Patients
Michael B. Streiff
drug therapy in women with stage II breast cancer . N Engl J Med 1988 ; 318 : 404 – 407 . 12. Pritchard KI Paterson AH Paul NA . Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of
Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS
Hiram S. Cody III and Kimberly J. Van Zee
: Findings from the National Surgical Adjuvant Breast and Bowel Project B-17 . J Clin Oncol 1998 ; 16 : 441 – 452 . 19 Fisher B Dignam J Wolmark N . Tamoxifen in the treatment of intraductal breast cancer: National Surgical Adjuvant Breast and
Introduction: Addressing Challenges in Multiple Myeloma Management in an Era of New Therapeutics
Sundar Jagannath
postmenopausal women with breast cancer in community and academic centers before and after the availability of ATAC (Adjuvant Tamoxifen, Arimidex or Combination) study [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1 ): Abstract 6621 . 13. McKibbin T
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer
Sushmita Gordhandas, William A. Zammarrelli III, Eric V. Rios-Doria, Angela K. Green, and Vicky Makker
tamoxifen exposure also increase EC risk. Individuals with Lynch syndrome and Cowden syndrome have genetic increased risk of EC, and emerging data indicate a potential role for BRCA1/2 germline pathogenic variants in the development of high-grade EC. 8 , 9
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Mary B. Daly, Tuya Pal, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L. Hutton, CGC, Beth Y. Karlan, Seema Khan, Catherine Klein, Wendy Kohlmann, CGC, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, LCGC, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Holly J. Pederson, Gwen Reiser, CGC, Leigha Senter-Jamieson, CGC, Kristen Mahoney Shannon, Rebecca Shatsky, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Matthew B. Yurgelun, Susan D. Darlow, and Mary A. Dwyer
has been suggested that the increased risk for endometrial cancer observed in some carriers of BRCA1/2 pathogenic or likely pathogenic variants may be due to the use of tamoxifen therapy by these women rather than the presence of a gene mutation. 118